Evidence map›Paper›PMID 39402285›Full record

ArticleWorld journal of microbiology & biotechnology2024

AVR/I/SSAPDB: a comprehensive & specialised knowledgebase of antimicrobial peptides to combat VRSA, VISA, and VSSA.

Rajat Kumar Mondal, Debayan Karmakar, Oshin Pal, Sintu Kumar Samanta

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rajat Kumar Mondal *Biochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, (IIIT-A), Devghat, Jhalwa, Prayagraj, Uttar Pradesh, 211012, India.
Debayan Karmakar *Biochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, (IIIT-A), Devghat, Jhalwa, Prayagraj, Uttar Pradesh, 211012, India.
Oshin Pal *Biochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, (IIIT-A), Devghat, Jhalwa, Prayagraj, Uttar Pradesh, 211012, India.
Sintu Kumar SamantaBiochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, (IIIT-A), Devghat, Jhalwa, Prayagraj, Uttar Pradesh, 211012, India. samantasintu@iiita.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise of multi-drug resistant (MDR) bacteria, especially strains of Staphylococcus aureus like Vancomycin-resistant S. aureus (VRSA), Vancomycin-intermediate S. aureus (VISA), and Vancomycin-susceptible S. aureus (VSSA), poses a severe threat to global health. This situation underscores the urgent need for novel antimicrobial agents to combat these resistant strains effectively. Here, we are introducing the Anti-Vancomycin-Resistant/Intermediate/Susceptible Staphylococcus aureus Peptide Database (AVR/I/SSAPDB), a manually curated comprehensive and specialised knowledgebase dedicated to antimicrobial peptides (AMPs) that target VRSA, VISA, and VSSA with clinical and non-clinical significance. Our database sources data from PubMed, cataloging 491 experimentally validated AMPs with detailed annotations on peptides, activity, and cross-references to external databases like PubMed, UniProt, PDB, and DrugBank. AVR/I/SSAPDB offers a user-friendly interface with simple to advanced and list-based search capabilities, enabling researchers to explore AMPs against VRSA, VISA, and VSSA. We are hoping that this resource will be helpful to the scientific community in developing targeted peptide-based therapeutics, providing a crucial tool for combating VRSA, VISA, and VSSA, and addressing a major public health concern. AVR/I/SSAPDB is freely accessible via any web-browser at URL: https://bblserver.org.in/avrissa/ .

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesKnowledge BasesStaphylococcus aureusDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsStaphylococcal InfectionsVancomycinVancomycin ResistanceAnti-Bacterial AgentsAntimicrobial PeptidesVancomycinAntimicrobial peptidesAVR/I/SSAPDBMDR bacteriaVancomycin-intermediate Staphylococcus aureusVancomycin-resistant Staphylococcus aureusVancomycin-susceptible Staphylococcus aureus

Identifiers

PMID39402285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.